Holen Sie sich die Stockscreener-App
4.17
3.47%
0.14
Handel nachbörslich:
4.17
Schlusskurs vom Vortag:
$4.03
Offen:
$4.09
24-Stunden-Volumen:
1.35M
Relative Volume:
1.04
Marktkapitalisierung:
$530.52M
Einnahmen:
$193.01M
Nettoeinkommen (Verlust:
$-12.15M
KGV:
-46.33
EPS:
-0.09
Netto-Cashflow:
$454.00K
1W Leistung:
+7.20%
1M Leistung:
+20.87%
6M Leistung:
-20.11%
1J Leistung:
-22.06%
1-Tages-Spanne:
$4.035
$4.19
1-Wochen-Bereich:
$3.68
$4.19
52-Wochen-Spanne:
$2.37
$7.63
Cytek Biosciences Inc Stock (CTKB) Company Profile
Firmenname
Cytek Biosciences Inc
Sektor
Branche
Telefon
(877) 922-9835
Adresse
47215 LAKEVIEW BOULEVARD, FREMONT
Vergleichen Sie CTKB mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CTKB
Cytek Biosciences Inc
|
4.17 | 512.71M | 193.01M | -12.15M | 454.00K | -0.09 |
|
ABT
Abbott Laboratories
|
129.40 | 228.03B | 43.11B | 13.94B | 6.78B | 7.98 |
|
BSX
Boston Scientific Corp
|
102.50 | 152.09B | 18.49B | 2.50B | 3.49B | 1.68 |
|
SYK
Stryker Corp
|
378.95 | 143.98B | 23.82B | 2.92B | 4.02B | 7.55 |
|
MDT
Medtronic Plc
|
92.91 | 117.98B | 33.54B | 4.69B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
77.68 | 45.17B | 5.69B | 1.41B | 577.90M | 6.95 |
Cytek Biosciences Inc Stock (CTKB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-05-09 | Herabstufung | TD Cowen | Buy → Hold |
| 2025-01-31 | Herabstufung | Goldman | Buy → Sell |
| 2023-12-14 | Eingeleitet | Stephens | Overweight |
| 2023-07-19 | Eingeleitet | Raymond James | Mkt Perform |
| 2022-01-06 | Fortgesetzt | Piper Sandler | Overweight |
Cytek Biosciences Inc Aktie (CTKB) Neueste Nachrichten
Cytek Biosciences to Participate in Upcoming Investor Conferences - GlobeNewswire
Cytek Biosciences Showcases Cell Analysis Innovation at UBS, Wells Fargo, Morgan Stanley Events - Stock Titan
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Cytek Biosciences (CTKB), Natera (NTRA) and Warby Parker (WRBY) - The Globe and Mail
Mixed Analyst Opinions on Healthcare Stocks Cytek Biosciences, Natera, and Warby Parker - AInvest
Cytek Biosciences Earnings Call Reveals Mixed Outlook - TipRanks
Cytek Biosciences, Inc. (NASDAQ:CTKB) Q2 2025 Earnings Call Transcript - Insider Monkey
Cytek Biosciences Second Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance
Cytek Biosciences Narrows FY25 Revenue Guidance to $196M-$200M - AInvest
Cytek narrows 2025 revenue outlook to $196M-$205M amid recurring revenue growth and new product launches - MSN
Cytek Biosciences 2025 Q2 Earnings Loss Narrows 50% as Revenue Slides 2.2% - AInvest
Cytek Biosciences Narrows 2025 Revenue Outlook to $196M-$205M Amid Recurring Revenue Growth and New Product Launches - AInvest
Cytek's 2025 Q2 Earnings: Navigating Contradictions in Sales, Margins, and Market Growth - AInvest
Earnings call transcript: Cytek Biosciences Q2 2025 misses revenue forecast By Investing.com - Investing.com South Africa
Earnings call transcript: Cytek Biosciences Q2 2025 misses revenue forecast - Investing.com
Cytek Biosciences: Q2 2025 Financial Performance Overview - TipRanks
Cytek Biosciences, Inc. (CTKB) Beats Q2 Earnings Estimates - sharewise.com
Transcript : Cytek Biosciences, Inc., Q2 2025 Earnings Call, Aug 06, 2025 - MarketScreener
Cytek Biosciences Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Cytek Biosciences, Inc. SEC 10-Q Report - TradingView
Cytek Biosciences earnings matched, revenue fell short of estimates By Investing.com - Investing.com Canada
Cytek Biosciences Reports Second Quarter 2025 Financial Results - GlobeNewswire
Press Release: Cytek Biosciences Reports Second Quarter 2025 Financial Results - 富途牛牛
Cytek Biosciences Inc. Stock Analysis and ForecastTremendous gains - Jammu Links News
What makes Cytek Biosciences Inc. stock price move sharplyUnlock exclusive stock analysis for investors - Jammu Links News
How does Cytek Biosciences Inc. compare to its industry peersMaximize your returns with smart trade entries - Jammu Links News
Is Cytek Biosciences Inc. a growth stock or a value stockBuild a winning portfolio with smart picks - Jammu Links News
What are the technical indicators suggesting about Cytek Biosciences Inc.Breakthrough capital growth - Jammu Links News
Does Cytek Biosciences Inc. stock perform well during market downturnsHigh-profit stock alerts - Jammu Links News
Should I hold or sell Cytek Biosciences Inc. stock in 2025Invest confidently with professional market insights - Jammu Links News
Is it the right time to buy Cytek Biosciences Inc. stockBuild your wealth with consistent stock growth - Jammu Links News
What catalysts could drive Cytek Biosciences Inc. stock higher in 2025Discover stock picks with superior returns - Jammu Links News
How strong is Cytek Biosciences Inc. company’s balance sheetFree Expert Stock Watchlist - Jammu Links News
What are the latest earnings results for Cytek Biosciences Inc.Capitalize on fast-moving trading opportunities - Jammu Links News
Can machine learning forecast Cytek Biosciences Inc. recoverySafe Momentum Strategy With Trend Analysis - Newser
Multi asset correlation models including Cytek Biosciences Inc.Institutional Holding Behavior Pattern Analysis - Newser
Using Bollinger Bands to evaluate Cytek Biosciences Inc.Real-Time AI Sentiment and Price Forecast - Newser
Real time social sentiment graph for Cytek Biosciences Inc.Free Weekly Hot Picks With Buy Confidence - Newser
Cytek Biosciences Inc.’s volatility index tracking explainedTrade Setups With AI Powered Filters Published - metal.it
Can Cytek Biosciences Inc. hit a new high this monthShort Term Opportunity Finder with Tools - Newser
Is Cytek Biosciences Inc. Stock Overbought or Oversold RSI Indicator AnalysisTrade Safety Matrix for Conservative Traders - Newser
Cytek Biosciences And 2 Other Penny Stocks Worth Watching - simplywall.st
How Interest Rate Changes Impact Cytek Biosciences Inc. Stock PerformanceEntry and Exit Strategy Optimizer Tool Tested - metal.it
What machine learning models say about Cytek Biosciences Inc.Risk Managed Intraday Trade Alerts Increase in Volume - metal.it
Finanzdaten der Cytek Biosciences Inc-Aktie (CTKB)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.31%
1.36%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):